Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4920)
°¨¿°Áúȯ (349)
°ñÁúȯ Ä¡·á (38)
´ç´¢º´ (194)
¹é½Å (180)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (44)
ºñó¹æ ÀǾàǰ (152)
¼öÀÇÇÐ (17)
½Å°æÁúȯ (174)
½Å¾à°³¹ß (1520)
¾ÏÄ¡·á (941)
¾à¹°Àü´Þ (185)
ÀǾàǰ ±ÔÁ¦È¯°æ (127)
Á¤½ÅÁúȯ (85)
Á¦³×¸¯ ÀǾàǰ (128)
Á¦¾àȸ»çºÐ¼® (522)
󹿾à (165)
Áö¿ªº°°Ë»ö
ÃâÆÇ»ç¿¡¼­ ã±â

Á¦¾àȸ»çºÐ¼® ½ÃÀåÁ¶»çº¸°í¼­ - Á¦¾à ±â¾÷ Á¤º¸

Á¦¾àȸ»çºÐ¼® ½ÃÀåÀ» Á¶»ç ºÐ¼®ÇÑ ÀÚ·á·Î ½ÃÀå ±Ô¸ð, »ê¾÷ ºÐ¼®, ÇâÈÄ ½ÃÀå ¿¹Ãø µîÀÇ ³»¿ëÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù.
º¸°í¼­¿¡ µû¶ó¼­ ÁÖ¿ä ±â¾÷ ºÐ¼®, °æÀïȯ°æ ºÐ¼®, ¿¬±¸°³¹ß ÇöȲ, ¿µ¾÷ Àü·«, ±â¾÷ Á¦ÈÞ ÇöȲÀ» Æ÷ÇÔÇÏ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù.


»ó¼¼ºÐ·ù
Á¦¸ñ°Ë»ö
1 - 25 ¸®ºä (Àüü£º 132 °Ç) Á¤·Ä Ç¥½Ã °Ç¼ö
»ùÇÃ
»óǰÄÚµå :239211
¼¼°è Á¦³×¸¯ ÀǾàǰ ½ÃÀåÀÇ À¯·Â ±â¾÷À» Æò°¡Çϱâ À§ÇÑ ÀڷḦ Á¦°øÇϱâ À§ÇØ »óÀ§ ±â¾÷ÀÇ 2012-2022³â ½ÇÀû ¿¹Ãø, Ãë±Þ Á¦Ç°, °æ¿µ ¹æÄ§, ±â¼ú °³¹ß, °æÀï ȯ°æ µî¿¡ °üÇÑ »ó¼¼ÇÑ Á¶»ç µ¥ÀÌÅ͸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,642
¹ßÇàÀÏ 2012³â 03¿ù
¸®¼­Ä¡»ç Visiongain
ÆäÀÌÁö¼ö 223 Pages
Cardiovascular Partnering Terms and Agreements
»ùÇÃ
¿­¶÷ ¼­ºñ½º Á¦°ø
»óǰÄÚµå :233135
±â¾÷ÀÇ ½ÉÇ÷°ü°è(Cardiovascular) ÆÄÆ®³Ê °Å·¡¿¡ ´ëÇØ Á¶»çÇϰí, ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀÇ 2007³â ÀÌÈÄ °Å·¡ µ¿Çâ, ÁÖ¿ä °Å·¡ ¹× °¡Àå Àû±ØÀûÀÎ °Å·¡ ±â¾÷ ºÐ¼®, °Å·¡ ±¸Á¶ ºÐ¼®, »ç·Ê ¿¬±¸, ±â¾÷ °³¿ä, µð·ºÅ丮¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,695
¹ßÇàÀÏ 2012³â 03¿ù
¸®¼­Ä¡»ç Current Partnering, a division of Wildwood Ventures Limited
ÆäÀÌÁö¼ö 769 Pages
Partnering Agreements with Bigpharma
»ùÇÃ
¿­¶÷ ¼­ºñ½º Á¦°ø
»óǰÄÚµå :232503
¼¼°è ´ëÇü Á¦¾àȸ»ç »óÀ§ 50»çÀÇ »ó¼¼ÇÑ Á¦ÈÞ È°µ¿ °³¿ä, 2007³â ÀÌÈÄÀÇ °Å·¡ Ȱµ¿, ¿¬µµº° °Å·¡ °Ç¼ö, °Å·¡ À¯Çü, »ê¾÷ ºÎ¹®, °³¹ß ´Ü°è, ±â¼ú Á¾·ù ¹× Ä¡·á ¿µ¿ªº° Ȱµ¿ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,695
¹ßÇàÀÏ 2012³â 02¿ù
¸®¼­Ä¡»ç Current Partnering, a division of Wildwood Ventures Limited
ÆäÀÌÁö¼ö  
Amylin Pharmaceuticals, Inc.: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :234126
Amylin PharmaceuticalsÀÇ 2016³â±îÁö ±â¾÷ Àü·«, ¸ÅÃâ Àü¸Á, ÀçÁ¤ »óÅ¿¡ ´ëÇØ Á¶»çÇϰí, Amylin PharmaceuticalsÀÇ ÁÖ¿ä Á¦Ç° »ó¼¼ ºÐ¼®, ȯÀÚ¿¡ ±Ù°ÅÇÑ ¿¹Ãø, ÁÖ¿ä ¿ÀÇǴϾ𠸮´õ ÀÎÅÍºä ºÐ¼® Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2012³â 02¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 36
MAP Pharmaceuticals: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :234127
MAP PharmaceuticalsÀÇ ±â¾÷ Àü·« ¹× SWOT¿¡ ´ëÇØ ºÐ¼®Çϰí, »ç·Â °³¿ä, À繫 ½ÇÀû ¿¹Ãø, ÁÖ¿ä ó¹æ Á¦Á¦ ºÐ¼®°ú ¸ÅÃâ ¿¹Ãø µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2012³â 02¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 29
Incyte Corporation: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :234128
IncyteÀÇ 2016³â±îÁö ±â¾÷ Àü·«, ¸ÅÃâ Àü¸Á, ÀçÁ¤ »óÅ¿¡ ´ëÇØ Á¶»çÇϰí, IncyteÀÇ ÁÖ¿ä Á¦Ç° »ó¼¼ ºÐ¼®, ȯÀÚ¿¡ ±Ù°ÅÇÑ ¿¹Ãø, ÁÖ¿ä ¿ÀÇǴϾ𠸮´õ ÀÎÅÍºä ºÐ¼® Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2012³â 02¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 36
»ùÇÃ
»óǰÄÚµå :230725
¼¼°è ÁÖ¿ä ÀÇ·á °ü·Ã »ç¾÷ÀÚÀÇ 2011³â Á¦ÈÞ ¹× M&A µ¿ÇâÀ» Á¶»ç ºÐ¼®Çϰí, 2011³â¿¡ ü°áµÈ M&A ¹× Á¦ÈÞ °è¾à °³¿ä(°Ç¼ö ¹× ±Ý¾× ±Ô¸ð), ´ë±Ô¸ð °è¾à°ú ´ëÇü »ç¾÷ÀÚ¿¡ ÀÇÇÑ °è¾à µîÀÇ »ó¼¼, »ê¾÷ ºÎ¹®, °è¾à Á¾·ù, °³¹ß ´Ü°è, Ä¡·á ºÎ¹®º° °¢Á¾ Á¦ÈÞ °è¾à µ¿Çâ, ÁÖ¿ä Á¦ÈÞ ¹× M&A °è¾à µð·ºÅ丮 µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,995
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç Urch Publishing, Ltd.
ÆäÀÌÁö¼ö 4000+ Pages
Dendreon Corporation: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :234117
DendreonÀÇ 2016³â±îÁö ±â¾÷ Àü·« ¹× ¸ÅÃâ Àü¸Á¿¡ ´ëÇØ Á¶»çÇϰí, DendreonÀÇ ÁÖ¿ä Á¦Ç° ¹× ÆÄÀÌÇÁ¶óÀÎ »ó¼¼ ºÐ¼®, ȯÀÚ¿¡ ±Ù°ÅÇÑ ¿¹Ãø, ÁÖ¿ä ¿ÀÇǴϾ𠸮´õ ÀÎÅÍºä ºÐ¼® Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 33
»ùÇÃ
¿­¶÷ ¼­ºñ½º Á¦°ø
»óǰÄÚµå :227852
ÀǾàǰ ¹× ÀÇ·á °ü·Ã »ç¾÷ÀÚÀÇ M&A, ±âŸ °¢Á¾ Á¦ÈÞ °è¾à µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, 2011³â¿¡ ü°áµÈ M&A °è¾à °³¿ä(°Ç¼ö ¹× ±Ý¾× ±Ô¸ð), ´ëÇü °è¾à, ´ëÇü »ç¾÷ÀÚÀÇ M&A °è¾à »ó¼¼, »ê¾÷ ºÎ¹®, °è¾à À¯Çü, °³¹ß ´Ü°è, Ä¡·á ºÐ¾ßº° °¢Á¾ Á¦ÈÞ °è¾à µ¿Çâ, M&A °è¾à µð·ºÅ丮 µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,995
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç Current Partnering, a division of Wildwood Ventures Limited
ÆäÀÌÁö¼ö 1000+ Pages
»ùÇÃ
¿­¶÷ ¼­ºñ½º Á¦°ø
»óǰÄÚµå :227851
ÀǾàǰ ¹× ÀÇ·á °ü·Ã »ç¾÷ÀÚÀÇ M&A ¹× °¢Á¾ Á¦ÈÞ °è¾à µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, 2011³â¿¡ ü°áµÈ M&A ¹× Á¦ÈÞ °è¾à °³¿ä(°Ç¼ö ¹× ±Ý¾× ±Ô¸ð), ´ëÇü °è¾à, ´ëÇü »ç¾÷ÀÚÀÇ °è¾à »ó¼¼, »ê¾÷ ºÎ¹®, °è¾à À¯Çü, °³¹ß ´Ü°è, Ä¡·á ºÐ¾ßº° °¢Á¾ Á¦ÈÞ µ¿Çâ, ÁÖ¿ä Á¦ÈÞ ¹× M&A °è¾à µð·ºÅ丮 µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,495
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç Current Partnering, a division of Wildwood Ventures Limited
ÆäÀÌÁö¼ö 5000+ Pages
»ùÇÃ
¿­¶÷ ¼­ºñ½º Á¦°ø
»óǰÄÚµå :227850
ÀǾàǰ ¹× ÀÇ·á °ü·Ã »ç¾÷ÀÚÀÇ °¢Á¾ Á¦ÈÞ °è¾à µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, 2011³â¿¡ ü°áµÈ Á¦ÈÞ °è¾à °³¿ä(°Ç¼ö ¹× ±Ý¾× ±Ô¸ð), ´ëÇü °è¾à ¹× ´ëÇü »ç¾÷ÀÚÀÇ Á¦ÈÞ °è¾à »ó¼¼, »ê¾÷ ºÎ¹®, °è¾à À¯Çü, °³¹ß ´Ü°è, Ä¡·á ºÐ¾ßº° °¢Á¾ Á¦ÈÞ °è¾à µ¿Çâ, ÁÖ¿ä Á¦ÈÞ °è¾à µð·ºÅ丮 µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,995
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç Current Partnering, a division of Wildwood Ventures Limited
ÆäÀÌÁö¼ö 4000+ Pages
Warner-Chilcott Plc: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :229458
ÀǾàǰ ¾÷°è¿¡¼­ÀÇ Warner-Chilcott PlcÀÇ ÇöÀç ¹× ÇâÈÄ ½ÇÀû µ¿Çâ¿¡ ´ëÇØ ºÐ¼®Çϰí, ÁÖ¿ä Á¦Ç° °³¹ß ¹× ÆÇ¸Å µ¿Çâ, À繫½ÇÀû ¹× ¿¹Ãø(ÃÑ 6°³³âºÐ), ±â¾÷ °³¿ä, »ç¾÷ Àü·« µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 62
Novartis AG: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :229457
ÀǾàǰ ¾÷°è¿¡¼­ÀÇ Novartis AG¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, ½ÇÀû ¹× ÇâÈÄ ¿¹Ãø, ±â¾÷ Àü·«, Æ÷Æ®Æú¸®¿À¿Í ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®, À繫 ½ÇÀû Æò°¡, 1-6°³³â ¸ÅÃâ ¿¹Ãø µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 103
Novo Nordisk A/S: PharmaVitae Profile
»ùÇÃ
»óǰÄÚµå :229407
ÀǾàǰ ¾÷°è¿¡¼­ÀÇ Novo Nordisk A/SÀÇ ÇöÀç ¹× ÇâÈÄ ½ÇÀû µ¿Çâ¿¡ ´ëÇØ ºÐ¼®Çϰí, ÁÖ¿ä Á¦Ç° °³¹ß ¹× ÆÇ¸Å µ¿Çâ, À繫½ÇÀû ¹× ¿¹Ãø(ÃÑ 6°³³â), ±â¾÷ °³¿ä, »ç¾÷ Àü·« µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 80
Pharmaceutical M&A in the Asia Pacific Region
»ùÇÃ
»óǰÄÚµå :229451
¾Æ½Ã¾ÆÅÂÆò¾ç Áö¿ªÀÇ ÀǾàǰ(Pharmaceutical) »ç¾÷ M&A¿¡ ´ëÇÑ ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, µ¿ÇâÀ» Á¶»çÇϰí, M&A Ȱµ¿ÀÇ Áö¿ª ¹× ±¹°¡º° ºÐ¼®, ÀÇ·á ºÐ¾ß¸¦ Ç¥ÀûÀ¸·ÎÇÑ Àμö »ç·Ê ºÐ¼®, °Å·¡ ±Ô¸ð, ÁÖ¿ä °Å·¡ Á¦Á¶¾÷ü¿¡ ´ëÇÑ Ãֽе¥ÀÌÅ͸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,600
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 72
CSL Limited: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :229447
ÀǾàǰ ¾÷°è¿¡¼­ÀÇ CSL LimitedÀÇ ÇöÀç ¹× ÇâÈÄ ½ÇÀû µ¿Çâ¿¡ ´ëÇØ ºÐ¼®Çϰí, ÁÖ¿ä Á¦Ç° °³¹ß ¹× ÆÇ¸Å µ¿Çâ, À繫½ÇÀû ¹× ¿¹Ãø(ÃÑ 6°³³â), ±â¾÷ °³¿ä, »ç¾÷ Àü·« µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 65
»ùÇÃ
»óǰÄÚµå :229446
¼¼°è Áß°ß Á¦¾à ±â¾÷(Mid Pharma Company)ÀÇ ÇâÈÄ Àü¸Á¿¡ ´ëÇØ ºÐ¼®Çϰí, ÇâÈÄ 6³â°£ÀÇ ½ÇÀû Àü¸Á, »ý»ê ¹× °³¹ß Àü·« Àü¸Á, ¼ºÀåÀÌ Àü¸ÁµÇ´Â ±â¾÷ ½ÇÀû ¿¹Ãø µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,800
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 38
Japan Pharma Company Outlook to 2016
»ùÇÃ
»óǰÄÚµå :229445
ÀϺ» Á¦¾à ¾÷°èÀÇ 2016³â±îÁö Àü¸Á¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, ÀϺ» ÀÚ±¹³» ÁÖ¿ä ±â¾÷ÀÇ Àü·«°ú »ç¾÷ ³»¿ë¿¡ °üÇÑ ¿¹Ãø µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,800
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 43
»ùÇÃ
»óǰÄÚµå :229443
¼¼°è ´ëÇü Á¦¾à ±â¾÷(Big Pharma Company)ÀÇ ÇâÈÄ Àü¸Á¿¡ ´ëÇØ ºÐ¼®Çϰí, ÇâÈÄ 6³â°£ÀÇ ½ÇÀû Àü¸Á, »ý»ê, °³¹ß, ¼ºÀå Àü·« Àü¸Á µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,800
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 50
Seattle Genetics, Inc.: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :229441
ÀǾàǰ ¾÷°è¿¡¼­ÀÇ Seattle Genetics, Inc.¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, ½ÇÀû ¹× ÇâÈÄ ¿¹Ãø, Á¦Ç° ºÐ¼®°ú ¿¹Ãø, ÆÄÀÌÇÁ¶óÀÎ Æò°¡, ±â¾÷ Àü·« Æò°¡, 6³â°£ÀÇ À繫 ½ÇÀû µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 34
Research Report on Top 50 Companies of China's Pharmaceutical Industry, 2011-2012
»ùÇÃ
»óǰÄÚµå :224494
Áß±¹ Á¦¾à »ê¾÷ÀÇ ´ë±â¾÷ 50»ç¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, ±â¾÷ °³¿ä, »ç¾÷ ¿î¿µ, ¹ßÀü Àü·« µî¿¡ ´ëÇØ ºÐ¼® ¹× Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,800
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç China Research and Intelligence
ÆäÀÌÁö¼ö Pages: 65
Key Companies: Osteoporosis - Growing competition threatens leading franchises and drives innovation
»ùÇÃ
»óǰÄÚµå :207802
°ñ´Ù°øÁõ Ä¡·á ½ÃÀå¿¡ °ü¿©ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÇ ºê·£µå ¼ö¸íÁÖ±â ¹× Æ÷Æ®Æú¸®¿À °ü¸® Àü·«¿¡ ´ëÇÑ °íÂû°ú Merck & Co.¹× ServierÀÇ °ñ´Ù°øÁõ Æ÷Æ®Æú¸®¿À °ü¸® Àü·«°ú °úÁ¦¿¡ ´ëÇÑ »ç·Ê¿¬±¸, º» ºÐ¾ß¿¡¼­ Ȱ¾àÇÏ´Â ±â¾÷ÀÇ Àü·« µ¿Çâ, ÃÖ±ÙÀÇ Áß¿ä ¶óÀ̼¾½º °è¾à¿¡ ÀÇÇÑ ¿µÇâ µî ÃֽŠÁ¶»ç Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,800
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 34
Merck KGaA: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :229422
ÀǾàǰ ¾÷°è¿¡¼­ÀÇ Merck KGaAÀÇ ÇöÀç ¹× ÇâÈÄ ½ÇÀû µ¿Çâ¿¡ ´ëÇØ ºÐ¼®Çϰí, ÁÖ¿ä Á¦Ç° °³¹ß ¹× ÆÇ¸Å µ¿Çâ, À繫½ÇÀû ¹× ¿¹Ãø(ÃÑ 6°³³â), ±â¾÷ °³¿ä, »ç¾÷ Àü·« µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 70
Gilead Sciences Inc.: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :229421
ÀǾàǰ ¾÷°è¿¡¼­ÀÇ Gilead Sciences Inc.ÀÇ ÇöÀç ¹× ÇâÈÄ ½ÇÀû µ¿Çâ¿¡ ´ëÇØ ºÐ¼®Çϰí, ÁÖ¿ä Á¦Ç° °³¹ß ¹× ÆÇ¸Å µ¿Çâ, À繫 ½ÇÀû ¹× ¿¹Ãø(ÃÑ 6°³³â°£), ±â¾÷ °³¿ä, »ç¾÷ Àü·« µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 71
Actelion Ltd: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :229420
ÀǾàǰ ¾÷°è¿¡¼­ÀÇ Actelion LtdÀÇ ÇöÀç ¹× ÇâÈÄ ½ÇÀû µ¿Çâ¿¡ ´ëÇØ ºÐ¼®Çϰí, ÁÖ¿ä Á¦Ç° °³¹ß ¹× ÆÇ¸Å µ¿Çâ, À繫½ÇÀû ¹× ¿¹Ãø(ÃÑ 6°³³â), ±â¾÷ °³¿ä, »ç¾÷ Àü·« µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 56